Ultromics is using artificial intelligence to give a better view of cardiovascular imaging. To further accomplish its goal, the company recently raised $33 million in a series B round.
The round was led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation.
Ultromics will use the new funding to help accelerate the use of AI-enabled echocardiograms to help improve patient care, and bring improved diagnostic quality and resource savings to hospitals.
The firm’s EchoGo Core and EchoGo Pro platforms quickly deliver highly accurate assessments of heart function that support the diagnosis of coronary artery disease, heart failure and amyloidosis. Both were spun out of the University of Oxford and built-in partnership with the U.K.'s National Health Service (NHS).
"Echocardiograms uploaded to the cloud and analyzed by artificial intelligence are set to revolutionize cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy," said Dr. Ross Upton, CEO and co-founder of Ultromics. "This funding with leading U.S.-affiliated venture capital funds will allow Ultromics to dramatically accelerate the use of AI-enhanced Echo into studies that currently use more expensive and, less accurate imaging techniques."